Entera Bio Ltd. (ENTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Entera Bio Ltd. (ENTX) closed at USD 2.77 on 2026-10-15, a change of +1.5 % over the past year, with a market capitalization of USD 465.88M.

Entera Bio Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Entera Bio Ltd. key figures

Previous close

USD 2.77 (2026-10-15)

1-year change

+1.5 %

Market cap

USD 465.88M

Enterprise value

USD 453.14M

P/E ratio (trailing)

-7.44

P/E ratio (forward)

-4.87

EPS (trailing)

-0.36

EPS (forward)

-0.55

PEG ratio

n/a

Price to book

18.23

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.80

Employees

20

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Entera Bio Ltd.

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Entera Bio Ltd. and compare it with other stocks.